D-0232-2022 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0232-2022 was initiated by Teva Pharmaceuticals USA on Oct 27, 2021 and is designated Class II. Reason for recall: Labelling: Incorrect Exp. Date The recall status is terminated (terminated Dec 21, 2022). Affected quantity: 32316 bottles.

Recall details

Product Type
Drugs
Report Date
Nov 24, 2021
Initiation Date
Oct 27, 2021
Termination Date
Dec 21, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
32316 bottles

Product description

Cartia XT (Diltiazem Hydrochloride Extended-Release Capsules, USP) 120 mg, Rx Only, 90 capsules, labelled as (a) Manufactured By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054; (b) Manufactured By: Actavis Laboratories FL. Inc, Fort Lauderdale FL. 33314 USA, Distributed by Avista Pharma Inc. Parsippany, NJ 07054 USA. NDC 62037-597-90

Reason for recall

Labelling: Incorrect Exp. Date

Distribution pattern

Distributed Nationwide in the USA

Code information

Lot # 100023805, Exp. Date 05/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0232-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0232-2022. Report a data issue: hello@regdatalab.com.